Twitter Facebook LinkedIn WhatsApp Press Releases (-) Any 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2022 April 28, 2022 argenx to Report First Quarter 2022 Financial Results and Business Update on May 5, 2022 April 5, 2022 argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART® (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis at 2022 AAN Annual Meeting April 1, 2022 argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting March 29, 2022 argenx announces full exercise of underwriters’ option to purchase additional ADSs March 29, 2022 argenx announces Annual General Meeting of Shareholders on May 10, 2022 March 28, 2022 argenx announces closing of global offering March 23, 2022 argenx raises $700 million in gross proceeds in a global offering March 22, 2022 argenx announces launch of proposed global offering March 22, 2022 argenx Announces Positive Topline Phase 3 Data from ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis March 3, 2022 argenx Reports Full Year 2021 Financial Results and Provides Fourth Quarter Business Update February 28, 2022 argenx to Present at the 42nd Annual Cowen Health Care Conference February 24, 2022 argenx to Report Full Year 2021 Financial Results and Fourth Quarter Business Update on March 3, 2022 Pagination First page « First Previous page ‹ Previous … Page 2 Page 3 Page 4 Page 5 Current page 6 Page 7 Page 8 Page 9 Page 10 … Next page Next › Last page Last »
